The U.S. Food and Drug Administration is taking a closer look at a potential safety concern involving three widely used breast cancer pills: Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). In its April through June 2026 quarterly report of potential safety signals, the FDA listed “colitis” next to these medicines and noted that it is “evaluating the need for regulatory action.” For people living with hormone receptor positive breast cancer, these CDK4/6 inhibitor drugs are mainstays of modern treatment, so any mention of a new risk can be unsettling. Understanding what a “safety signal” means, and what symptoms should prompt a call to the oncology team, is key to navigating this news.

At the center of this development is the distinction between a potential concern and a confirmed drug risk. The FDA regularly reviews reports of side effects submitted by clinicians, patients, and manufacturers through its Adverse Event Monitoring System. When the agency detects a pattern worth investigating, it lists the medicine and the possible side effect in a quarterly update. That is what has happened now with Ibrance, Kisqali, Verzenio, and colitis. The appearance of a drug on this list does not mean regulators have concluded that the medicine causes the problem. In fact, the FDA explicitly states that a listing alone does not confirm a risk and does not mean that patients should stop taking their treatment.

This nuance is important because real-world safety reports come with limitations. Submissions are voluntary and often incomplete. They cannot establish how common a problem is or prove that a particular medicine caused it. Many people with breast cancer receive combinations of drugs and have other health conditions that could contribute to bowel inflammation. The agency has not disclosed how many colitis reports it has received in connection with these drugs, how severe those cases were, or whether the pattern differs from one CDK4/6 inhibitor to another. Investigators will need to explore those questions before any firm conclusions are drawn.

Colitis refers to inflammation of the large intestine. It can cause abdominal pain, bloating, urgent and frequent bowel movements, diarrhea, and sometimes blood in the stool. In severe cases it may lead to dehydration, fever, or complications that require urgent care. By contrast, diarrhea on its own is a much more common and already well recognized side effect of Ibrance, Kisqali, and particularly Verzenio. That overlap between expected diarrhea and relatively rare bowel inflammation is exactly what makes this issue challenging for patients and caregivers.

All three drugs on the FDA’s safety signal list belong to a class that blocks proteins called CDK4 and CDK6, which help cancer cells divide. They are approved for hormone receptor positive, HER2 negative breast cancer, often together with hormone therapy. Kisqali and Verzenio also have approvals in the early breast cancer setting for certain people at higher risk of recurrence, which has broadened the number of individuals exposed to these medicines. In that context, understanding both common and uncommon side effects becomes even more important, not because therapy should stop, but because timely symptom reporting can prevent complications.

The current prescribing information reflects what clinical trials and post-approval monitoring have already taught researchers. Diarrhea is featured prominently on the Verzenio label, which reports that between 81 percent and 90 percent of study participants experienced it, with severe (grade 3) diarrhea in 8 percent to 20 percent. The labels for Ibrance and Kisqali also identify diarrhea as a known side effect. None of the three labels, however, currently mentions colitis as a specific risk. That is one reason the FDA’s evaluation could eventually result in label updates if a link is supported by additional data.

This would not be the first time the agency has taken action on the CDK4/6 inhibitor class. In 2019, the FDA warned about rare but serious lung inflammation associated with Ibrance, Kisqali, and Verzenio. That communication led to new information on the prescribing labels and guidance about monitoring for respiratory symptoms. Even at that time, the agency stressed that people should not stop these cancer medicines without consulting their health care team. The same approach applies now, as there has been no change in official treatment guidance related to colitis.

For patients and caregivers, the practical question is how to distinguish routine treatment related diarrhea from bowel symptoms that could signal something more concerning. According to MedlinePlus, colitis can produce abdominal pain and bloating, bloody stools, a constant urge to have a bowel movement, diarrhea, dehydration, and fever. The article notes that anyone taking Ibrance, Kisqali, Verzenio, or the Kisqali Femara Co-Pack should contact their oncology team promptly if they notice blood in the stool or black, tarry stools, abdominal pain that does not improve, diarrhea that fails to get better with the plan their team has provided, fever paired with diarrhea, or warning signs of dehydration such as dizziness or very dark urine.

Some situations rise to the level of a medical emergency. Severe abdominal pain, heavy rectal bleeding, fainting, or confusion warrant urgent care. Because it can be difficult in the moment to recall when symptoms started or how they changed, caregivers can play a useful role by tracking bowel habits and treatments. A simple log that notes the number of bowel movements, their consistency, any visible blood, and use of anti-diarrhea medicines can give clinicians a clearer picture of whether the pattern still fits expected diarrhea or suggests possible colitis.

People most likely to feel the impact of any new safety information include those with metastatic breast cancer who may take CDK4/6 inhibitors for long periods and older adults, who can become dehydrated more quickly. A 2022 analysis from the National Cancer Institute published in JNCI estimated that about 140,230 women in the United States were living with metastatic breast cancer as of 2018 and projected that this number would rise to approximately 169,000 by 2025. Many of these individuals are candidates for therapies such as Ibrance, Kisqali, or Verzenio, so even rare complications draw careful scrutiny.

Despite understandable concern, the article emphasizes that patients should not stop, skip, or cut doses of their breast cancer medicine on their own. Doing so can reduce the treatment’s effectiveness against the cancer. Any decision to adjust a dose, pause therapy, or switch drugs should come from the prescribing oncologist, ideally after a thorough discussion of symptoms and risks. Those who are unsure whether their current bowel issues are “normal” for these medicines are encouraged to ask their oncologist or pharmacist to review what they are experiencing and to clarify which red flag symptoms require immediate contact.

As for what happens next, the FDA has several options. After it completes its review of colitis reports with Ibrance, Kisqali, and Verzenio, the agency may decide that no change is needed. It could ask manufacturers to add colitis to the prescribing information, issue additional safety communications, or take other regulatory steps. No timeline has been announced, and, according to the article, there have been no public statements from Pfizer, Novartis, or Eli Lilly, the companies that market these drugs. In the meantime, clinicians and patients can contribute to safety monitoring by reporting suspected side effects through the FDA’s MedWatch program.

For now, the main takeaway is one of vigilance rather than alarm. The FDA is investigating a possible link between these CDK4/6 inhibitors and colitis, but such a connection has not been confirmed and current treatment recommendations remain unchanged. People taking Ibrance, Kisqali, or Verzenio can continue their therapy while staying alert to warning signs such as blood in the stool, persistent abdominal pain, unrelenting diarrhea, fever, or dehydration. Prompt reporting of concerning symptoms and collaborative decision making with the oncology team remain the most effective ways to stay safe while preserving the benefits of these important breast cancer drugs. Read more at https://www.medicaldaily.com/fda-colitis-signal-ibrance-kisqali-verzenio-breast-cancer-479548